Genentech, Inc.
http://www.gene.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Genentech, Inc.
Aurobindo One Step Closer To Xolair Biosimilar Registration
With originator Xolair’s patents already expired or about to end next year, Aurobindo’s CuraTeQ is on track with its omalizumab biosimilar for regulatory filings in 2024/2025, following a Phase I trial completion.
Boosting Complex Innovative Designs In Clinical Trials: What The Pilots Show
Lilly representative suggests having more informal communication with FDA and consistent feedback across divisions. The firm had a positive experience participating in CID pilot with master protocol for chronic pain therapies.
Genmab's Growth Strategy: Embracing A ‘Super Rational, Data-Driven' Mindset
The “Genmab sauce” will be crucial as the Danish biotech loads up on late-stage assets, grows its capabilities and expands into immunology and inflammation.
Celltrion Leads Xolair Biosimilar Race With US FDA Application
This marks Celltrion’s second regulatory submission for an omalizumab biosimilar as the US formulation patent protecting originator Xolair is set to expire late next year.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- Tanox
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice